Lilly names Lucas Montarce chief financial officer

Eli Lilly announced on Sept. 9, 2024, that it had appointed Lucas Montarce as executive vice president and chief financial officer, effective immediately ^[1]. The move filled a post left open after former CFO Anat Ashkenazi departed to join Google parent Alphabet ^[2].

Montarce is not new to the company. He joined Lilly in 2001 and spent more than two decades moving through finance roles, including chief financial officer of Lilly Research Laboratories, chief financial officer of Lilly International, and global chief financial officer of Elanco Health ^[1]. Most recently, he served as president and general manager of Lilly's Spain, Portugal and Greece hub, a role he had taken on earlier in 2024 ^[1][2]. Lilly Chair and CEO David A. Ricks said the appointment followed "a competitive search across health care, tech and general industries" and that he had worked directly with Montarce for more than a decade ^[1]. In his new role, Montarce is set to earn a base salary of $1 million with eligibility for an annual target bonus of $1 million ^[2].

The leadership change came as Lilly was investing heavily in manufacturing capacity to keep up with demand for its diabetes and obesity drugs Mounjaro and Zepbound, both containing the molecule tirzepatide ^[2]. At the time, Lilly's products were listed as available by the Food and Drug Administration but had still spent most of the year on the agency's official shortage list ^[2]. Shares of Lilly rose about 1% to $910 in premarket trading the morning the appointment was announced, and the company was already described as the world's most valuable health care company, a status CNBC attributed largely to demand for its weight-loss treatments ^[2]. Analysts cited by CNBC projected the broader weight-loss drug market, where Lilly competes with Novo Nordisk, could exceed $150 billion by the early 2030s ^[2].

The sources do not specify Lilly's total market value on the day of the announcement or trace how that figure changed in the following months; that detail is not covered in the material provided here.

Why it matters for patients

A CFO appointment does not change a drug's price, coverage, or availability on its own. But it signals how a company is organizing itself around a product line. Lilly's move came while its tirzepatide medicines, Mounjaro and Zepbound, remained on the FDA's shortage list even after being marked as available ^[2], a status that has affected pharmacy access for some patients. Investors and executives increasingly framed Lilly's financial identity around incretin drugs and the manufacturing buildout needed to supply them ^[2], which matters to patients because production capacity, not just demand, has been a limiting factor in getting prescriptions filled.

Patients weighing these drugs are not directly affected by who holds the CFO title, but the continuity Lilly emphasized, an internal 23-year veteran stepping into finance leadership at a moment of rapid growth, points to a company trying to steady its operations while scaling up supply of drugs many patients are waiting to access ^[1][2].

What happens next

The sources provided do not detail Montarce's specific priorities once in the role or give a timeline for resolving the Mounjaro and Zepbound shortage listing beyond the September 2024 snapshot ^[2]. Any later developments in manufacturing capacity, shortage status, or Lilly's market valuation are not addressed in the material available here.